Therapy Detail

Therapy Name SYM004
Therapy Description

Symphogen (Sym004) is comprised of two antibodies that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SYM004 Symphogen EGFR Antibody 27 Symphogen (Sym004) is comprised of two antibodies that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NRAS mutant colorectal cancer predicted - resistant SYM004 Preclinical - Pdx Actionable In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). 29423521
KRAS mutant colorectal cancer predicted - resistant SYM004 Preclinical - Pdx Actionable In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). 29423521
KRAS wild-type colorectal cancer no benefit SYM004 Phase II Actionable In a Phase II trial, SYM004 treatment did not improve overall survival compared to standard of care in patients with metastatic colorectal cancer harboring no KRAS exon 2 mutations, and acquired resistance to anti-EGFR therapy (PMID: 29423521). 29423521
BRAF mutant colorectal cancer predicted - resistant SYM004 Preclinical - Pdx Actionable In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). 29423521
Clinical Trial Phase Therapies Title Recruitment Status
NCT02540161 Phase II SYM004 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Recruiting
NCT02965417 Phase II SYM004 Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Withdrawn
NCT02083653 Phase II SYM004 Fluorouracil Capecitabine Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Completed
NCT03549338 Phase II Modotuximab Futuximab SYM004 Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Active, not recruiting